Oxidative stress sensor Keap1 recognizes HBx protein to activate the Nrf2/ARE signaling pathway, thereby inhibiting hepatitis B virus replication.

HBx Keap1/Nrf2/ARE hepatitis B virus

Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
06 Oct 2023
Historique:
medline: 6 10 2023
pubmed: 6 10 2023
entrez: 6 10 2023
Statut: aheadofprint

Résumé

Hepatitis B virus (HBV) infection promotes reactive oxygen species production while paradoxically inducing the expression of antioxidant enzymes. HBV-induced disorders of redox homeostasis are closely associated with the development of hepatic diseases. However, the molecular mechanisms underlying the HBV-induced antioxidant response are poorly understood. The NF-E2-related factor 2 (Nrf2)/antioxidant response element (ARE) signaling pathway is an intrinsic defense mechanism against oxidative stress. We here aim to elucidate the role of the Nrf2/ARE signaling pathway in the HBV life cycle. ARE-driven reporter assays revealed that expression of HBV X protein (HBx), but not HBV core, large HBV surface, or HBV polymerase, strongly enhanced ARE-luciferase activity, suggesting that HBx plays an important role in the HBV-induced antioxidant response. Knockdown of Nrf2 resulted in a marked decrease in HBx-induced ARE-luciferase activity. Immunoblot analysis and immunofluorescence staining suggested that HBx activates Nrf2 by increasing Nrf2 protein levels and enhancing Nrf2 nuclear localization. The oxidative stress sensor Kelch-like ECH-associated protein 1 (Keap1) is required for the ubiquitin-dependent degradation of Nrf2. Coimmunoprecipitation analysis revealed that HBx interacted with Keap1, suggesting that HBx competes with Nrf2 for interaction with Keap1. A cell-based ubiquitylation assay showed that HBx promoted polyubiquitylation of Nrf2 via K6-linked polyubiquitin chains, and that this action may be associated with Nrf2 stabilization. A chromatin immunoprecipitation assay suggested that Nrf2 interacts with the HBV core promoter. Overexpression of Nrf2 strongly suppressed HBV core promoter activity, resulting in a marked reduction in viral replication. Based on the above, we propose that Keap1 recognizes HBx to activate the Nrf2/ARE signaling pathway upon HBV infection, thereby inhibiting HBV replication.IMPORTANCEThe Kelch-like ECH-associated protein 1 (Keap1)/NF-E2-related factor 2 (Nrf2)/antioxidant response element (ARE) signaling pathway is one of the most important defense mechanisms against oxidative stress. We previously reported that a cellular hydrogen peroxide scavenger protein, peroxiredoxin 1, a target gene of transcription factor Nrf2, acts as a novel HBV X protein (HBx)-interacting protein and negatively regulates hepatitis B virus (HBV) propagation through degradation of HBV RNA. This study further demonstrates that the Nrf2/ARE signaling pathway is activated during HBV infection, eventually leading to the suppression of HBV replication. We provide evidence suggesting that Keap1 interacts with HBx, leading to Nrf2 activation and inhibition of HBV replication via suppression of HBV core promoter activity. This study raises the possibility that activation of the Nrf2/ARE signaling pathway is a potential therapeutic strategy against HBV. Our findings may contribute to an improved understanding of the negative regulation of HBV replication by the antioxidant response.

Identifiants

pubmed: 37800948
doi: 10.1128/jvi.01287-23
pmc: PMC10617466
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0128723

Références

J Biol Chem. 2004 Apr 9;279(15):15460-71
pubmed: 14724286
Cell Death Dis. 2015 Nov 19;6:e1980
pubmed: 26583321
J Virol. 2019 Mar 5;93(6):
pubmed: 30567989
J Virol. 2002 Dec;76(24):13001-14
pubmed: 12438626
Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):2040-5
pubmed: 14764894
Free Radic Res. 1999 Oct;31(4):261-72
pubmed: 10517532
J Biol Chem. 2010 Dec 24;285(52):41074-86
pubmed: 20956535
Hepatol Commun. 2022 Feb;6(2):281-296
pubmed: 34558845
PLoS Pathog. 2022 Feb 9;18(2):e1009986
pubmed: 35139135
Microbiol Immunol. 2016 Jan;60(1):17-25
pubmed: 26616333
Antiviral Res. 2019 Jan;161:53-62
pubmed: 30465784
Science. 2004 Feb 27;303(5662):1371-4
pubmed: 14739464
J Virol. 2008 Nov;82(21):10375-85
pubmed: 18768989
Nat Commun. 2020 Oct 2;11(1):4938
pubmed: 33009401
Pharmacol Res. 2018 Aug;134:92-99
pubmed: 29913224
Oncotarget. 2017 Jan 17;8(3):3895-3932
pubmed: 27965466
Nat Rev Drug Discov. 2013 Dec;12(12):931-47
pubmed: 24287781
J Exp Med. 2013 Jul 29;210(8):1529-44
pubmed: 23857982
J Gen Virol. 2021 Oct;102(10):
pubmed: 34661519
Nat Rev Drug Discov. 2004 Mar;3(3):205-14
pubmed: 15031734
Curr Trends Immunol. 2016;17:117-123
pubmed: 28133423
Virology. 2017 Mar;503:1-5
pubmed: 28068513
Nat Cell Biol. 2010 Mar;12(3):213-23
pubmed: 20173742
Antiviral Res. 2019 Sep;169:104537
pubmed: 31207277
Cell Death Differ. 2016 Apr;23(4):616-27
pubmed: 26794444
Nat Rev Dis Primers. 2018 Jun 07;4:18035
pubmed: 29877316
Annu Rev Biochem. 2017 Jun 20;86:715-748
pubmed: 28441057
Nat Rev Drug Discov. 2019 Nov;18(11):827-844
pubmed: 31455905
Mol Cell Biol. 2012 Apr;32(8):1506-17
pubmed: 22331464
Mol Cell Biol. 2001 Nov;21(22):7721-30
pubmed: 11604508
Cell Rep. 2014 Mar 27;6(6):1017-1025
pubmed: 24630991
Antioxid Redox Signal. 2010 Dec 1;13(11):1699-712
pubmed: 20486766
J Virol. 2007 Feb;81(3):1174-85
pubmed: 17108031
J Gen Virol. 2014 May;95(Pt 5):991-1004
pubmed: 24496828
Free Radic Biol Med. 2015 Nov;88(Pt B):93-100
pubmed: 26117331
Mol Cell Biol. 2020 Jun 15;40(13):
pubmed: 32284348
Mol Cell Biol. 2006 Apr;26(8):2887-900
pubmed: 16581765
Cancer Res. 2013 Apr 1;73(7):2199-210
pubmed: 23382044
Nature. 2001 Dec 13;414(6865):813-20
pubmed: 11742414
EMBO J. 2014 Nov 3;33(21):2473-91
pubmed: 25216678
Mol Cell Biochem. 2006 Oct;290(1-2):79-85
pubmed: 16960659
J Virol. 2021 Jul 12;95(15):e0076721
pubmed: 33980595
J Biol Chem. 2009 May 15;284(20):13291-5
pubmed: 19182219
Mol Cell. 2017 Oct 5;68(1):233-246.e5
pubmed: 28943312
World J Gastroenterol. 2015 Jun 14;21(22):6872-83
pubmed: 26078563
J Virol. 2016 Jan 20;90(7):3530-42
pubmed: 26792738
Biochem Biophys Res Commun. 2014 Jan 17;443(3):808-13
pubmed: 24342612
Hepatology. 2006 Oct;44(4):915-24
pubmed: 17006908
J Virol. 2013 Apr;87(8):4360-71
pubmed: 23388725
Ann Clin Biochem. 2009 Sep;46(Pt 5):394-400
pubmed: 19641006
J Gen Virol. 2015 Jul;96(Pt 7):1850-4
pubmed: 25828947
Cancer Lett. 2013 Apr 30;331(1):76-83
pubmed: 23246371
Sci Rep. 2020 Jan 22;10(1):941
pubmed: 31969598
J Biol Chem. 2013 Nov 1;288(44):31715-27
pubmed: 24025329
J Biol Chem. 2012 Feb 24;287(9):6539-50
pubmed: 22215675
J Hepatol. 2001 Nov;35(5):613-8
pubmed: 11690707
Biochem Biophys Res Commun. 2014 Sep 26;452(3):315-21
pubmed: 25150444
Nat Commun. 2019 Oct 25;10(1):4878
pubmed: 31653857
Nat Rev Dis Primers. 2016 Apr 14;2:16018
pubmed: 27158749

Auteurs

Adi Ariffianto (A)

Division of Infectious Disease Control, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan.
Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.

Lin Deng (L)

Division of Infectious Disease Control, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan.

Takayuki Abe (T)

Division of Infectious Disease Control, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan.

Chieko Matsui (C)

Division of Infectious Disease Control, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan.

Masahiko Ito (M)

Department of Virology and Parasitology, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Akihide Ryo (A)

Department of Virology III, National Institute of Infectious Diseases, Tokyo, Japan.

Hussein Hassan Aly (HH)

Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.

Koichi Watashi (K)

Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.
Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.

Tetsuro Suzuki (T)

Department of Virology and Parasitology, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Masashi Mizokami (M)

Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan.

Yoshiharu Matsuura (Y)

Center for Infectious Disease Education and Research (CiDER), Osaka University, Osaka, Japan.
Laboratory of Virus Control, Research Institute for Microbial Diseases (RIMD), Osaka University, Osaka, Japan.

Ikuo Shoji (I)

Division of Infectious Disease Control, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan.

Classifications MeSH